biomarkers – Medxy AI

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

By MedXY 02/06/2026

Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiveness in detecting amyloid-β pathology.

news Pathology & Lab Medicine Respiratory

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

By MedXY 01/31/2026

Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchitis, offering a more precise tool for diagnosing and tracking muco-obstructive lung diseases.

Cardiology news

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

By MedXY 01/22/2026

This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFpEF, highlighting the roles of inflammation and adipose metabolism.

Gastroenterology news Oncology

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma

By MedXY 01/19/2026

A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and precision oncology.

Cardiology Critical Care news

Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock

By MedXY 01/18/2026

A large-scale proteomic analysis identifies VEGFR1 as a significant, independent predictor of 180-day mortality in patients with cardiogenic shock, offering incremental prognostic value beyond traditional markers like serum lactate and SAPS II scores.

Cardiology Internal Medicine news

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

By MedXY 01/18/2026

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting the complexities of implementing precision medicine in clinical practice.

Cardiology Diabetes & Endocrinology news

Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients

By MedXY 01/17/2026

A post hoc analysis of the SPRINT trial reveals that the coexistence of prediabetes and subclinical myocardial injury or stress significantly escalates heart failure risk in hypertensive adults, suggesting a need for integrated glycemic and biomarker screening.

news Oncology

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

By MedXY 01/14/2026

Updated ASTRUM-005 results confirm serplulimab's significant survival benefit in extensive-stage small-cell lung cancer (15.8 vs. 11.1 months). Exploratory analyses identify a 15-protein signature and RB1/Notch mutations as potential predictive biomarkers for immunotherapy response.

news Pediatrics Rheumatology

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial

By MedXY 01/13/2026

A post-hoc analysis of the Phase 3 JUVE-BASIS trial identifies key serum biomarkers, including CCL7, CCL18, and IL-6, that correlate with clinical response to baricitinib in JIA, suggesting potential pathways for personalized JAK inhibitor therapy.

news Oncology Urology

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

By MedXY 01/12/2026

A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MSI as a viable alternative for patient selection.

news Oncology Urology

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

By MedXY 01/12/2026

A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for patient selection when tissue is limited.

Cardiology Diabetes & Endocrinology news

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease

By MedXY 01/09/2026

Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved risk stratification beyond traditional clinical factors.

Neurology news

Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency

By MedXY 01/07/2026

A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and multiple sclerosis.

Neurology news Radiology

Midlife Plasma GFAP as a Long-Term Sentinel for Cerebral Small Vessel Disease: A Decadal Prospective Study

By MedXY 01/06/2026

Elevated plasma glial fibrillary acidic protein (GFAP) in middle age independently predicts the progression of cerebral small vessel disease MRI markers nearly a decade later, suggesting its potential as an early-stage prognostic biomarker for neurovascular decline.

Cardiology Hematology-Oncology news

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients

By MedXY 01/05/2026

A post hoc analysis of the AVERT trial identifies GDF-15, NT-proBNP, CRP, and hs-TnT as significant predictors for venous thromboembolism and bleeding in cancer patients, offering new tools for personalized risk stratification.

Clinical Updates Neurology news Pathology & Lab Medicine

Precision Screening for Preclinical Alzheimer Disease: The Ascendance of Plasma p-tau217 as a Scalable Biomarker

By MedXY 01/02/2026

This review synthesizes recent high-impact evidence on plasma p-tau217, demonstrating its superior utility in identifying amyloid pathology, predicting cognitive decline, and optimizing recruitment for primary prevention trials in cognitively unimpaired individuals.

Diabetes & Endocrinology Nephrology news

Beyond eGFR and UACR: kidneyintelX.dkd Refines Risk Stratification and Monitors Treatment Response in Diabetic Kidney Disease

By MedXY 12/31/2025

A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kidney disease.

AI General Surgery news

Predicting Post-Hepatectomy Liver Failure with the PILOT Architecture: Integrating Liver Regeneration Biomarkers and Time-Phased Machine Learning

By MedXY 12/29/2025

The novel PILOT machine learning architecture integrates time-phased perioperative data and regeneration-associated biomarkers to predict post-hepatectomy liver failure within six hours of surgery, significantly outperforming traditional clinical models and enabling early personalized risk stratification.

Cardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

By MedXY 12/24/2025

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.

Cardiology news

Long-Term Silicon Exposure Fails to Predict Coronary Artery Disease Severity or Systemic Inflammation

By MedXY 12/24/2025

A pilot study evaluating hair silicon as a long-term mineral marker found no significant association between silicon concentrations and coronary artery disease (CAD) severity or inflammatory markers, suggesting silicon may be metabolically neutral in advanced atherosclerosis.